Indivior Pharmaceuticals and Supernus Pharmaceuticals have merged. Learn More Here
Displaying 1 - 10 of 23

Indivior merger with Supernus Pharmaceuticals

Supernus Logo

As of November 2, 2026, Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have successfully completed their merger of equals transaction, creating a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, financial flexibility and capacity to pursue growth opportunities, and a differentiated pipeline. The combined company will operate as Supernus, Inc. and will trade on the Nasdaq Global Select Market beginning on November 3, 2026, under the ticker symbol "SUPN".

Learn more about the merger